Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
14 Oct, 07:56 PM
XSTU XSTU
€
227. 25
+4.95
+2.2267%
€
- Market Cap
29.06 P/E Ratio
0.69% Div Yield
1,723 Volume
9.91 Eps
€ 222.3
Previous Close
Add Transaction
Day Range
222.1 227.35
Year Range
158.92 241.15
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

JNJ closed yesterday higher at €227.25, an increase of 2.2267% from Tuesday's close, completing a monthly decrease of -0.6992% or -€1.6. Over the past 12 months, JNJ stock gained 29.2956%.
JNJ pays dividends to its shareholders, with the most recent payment made on Sep 08, 2026. The next announced payment will be in In 1 month on Dec 08, 2026 for a total of €1.34.
The last earnings report, released on Apr 14, 2026, missed the consensus estimates by -2.69%. On average, the company has fell short of earnings expectations by -2.64%, based on the last three reports.
Johnson & Johnson has completed 6 stock splits, with the recent split occurring on Jun 13, 2001.
The company's stock is traded on 18 different exchanges and in various currencies, with the primary listing on NYSE (USD).

JNJ Chart

JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges

JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges

Johnson & Johnson raises its 2026 sales and earnings outlook as strong pharmaceutical growth offsets MedTech challenges, while 2027 dilution clouds the outlook.

Zacks | 1 day ago
J&J Beat and Raised. The Stock Fell Anyway.

J&J Beat and Raised. The Stock Fell Anyway.

Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.

247wallst | 1 day ago
Johnson & Johnson: Keep Calm And Hold On

Johnson & Johnson: Keep Calm And Hold On

Johnson & Johnson delivered resilient sales growth and a beat-and-raise quarter, but profitability softness and regulatory risks warrant caution. Innovative Medicine segment shows promise with positive late-stage trial data, while MedTech's OTTAVA system could drive future growth. Despite operational strength, Johnson & Johnson's forward P/E and PEG ratios are at significant premiums, making current valuation unattractive for new accumulation.

Seekingalpha | 2 days ago

Johnson & Johnson (JNJ) FAQ

What is the stock price today?

The current price is €227.25.

On which exchange is it traded?

Johnson & Johnson is listed on XSTU.

What is its stock symbol?

The ticker symbol is JNJ.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.69%.

What is its market cap?

As of today, no market cap data is available.

Has Johnson & Johnson ever had a stock split?

Johnson & Johnson had 6 splits and the recent split was on Jun 13, 2001.

Johnson & Johnson Profile

Media Industry
Communication Services Sector
Joaquin Duato CEO
XSTU Exchange
478160104 CUSIP
US Country
141,700 Employees
25 Aug 2026 Last Dividend
13 Jun 2001 Last Split
- IPO Date

Overview

Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.

Products and Services

The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:

  • Innovative Medicine:

    This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.

  • MedTech:

    This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Contact Information

Address: One Johnson & Johnson Plaza
Phone: 732 524 0400